Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Sponsor: Edison Pharmaceuticals Inc
Listed as NCT02300753, this observational or N/A phase trial focuses on Leber's Hereditary Optic Neuropathy and remains ongoing. Sponsored by Edison Pharmaceuticals Inc, it has been updated 8 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)Emergency use administration of EPI-743 to subjects with LHON. This Protocol was originally developed to treat a single subject but was expanded to treat several at a single institution.
Emergency use administration of EPI-743 to subjects with LHON. This Protocol was originally developed to treat a single subject but was expanded to treat several at a single institution.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
No Longer Available
-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Edison Pharmaceuticals Inc
For direct contact, visit the study record on ClinicalTrials.gov .